What does Inhalon Biopharma do?

Clinical-stage biotech developing inhaled antibody treatments for acute respiratory infections such as RSV, hMPV and influenza.

Who founded Inhalon Biopharma?

Inhalon Biopharma was founded by Samuel Lai, Sam Lai in 2018.

Who are Inhalon Biopharma's investors?

Inhalon Biopharma's investors include Berkeley Catalyst, Flucas Ventures.

How much funding has Inhalon Biopharma raised?

Inhalon Biopharma has disclosed $2.9M raised across 1 round.

Where is Inhalon Biopharma headquartered?

Inhalon Biopharma is headquartered in Carrboro, US.

Inhalon Biopharma

Carrboro, US · Founded 2018 · Delaware corporation · 2 known investors

Inhalon Biopharma is a clinical-stage biotechnology company developing inhaled "muco-trapping" antibody treatments for acute respiratory infections, including RSV, influenza, human metapneumovirus, and SARS-CoV-2. Its therapies aim to treat active infection directly in the lung.

Also known as Inhalon

Biotech Healthtech

Founders & leadership

Inhalon Biopharma was founded in 2018 by Samuel Lai and Sam Lai.

Samuel LaiCo-founder

Sam LaiFounder

John WhelanChief Executive Officer

John B. WhelanNamed on SEC filing

Winnie WanNamed on SEC filing

Investors · 2

Berkeley CatalystBerkeley

Flucas VenturesJupiter · $100K – $5Mvia Ashley Flucas · inferred

Reported raises · per SEC filings

Form D private placements

$2.9M disclosed across 1 round · 2020

▶$2.9MraisedSep 2020 · 15 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

John B. WhelanExecutive Officer, Director
Winnie WanDirector
Samuel LaiExecutive Officer, Director

Offering amount: $3.6M
Amount sold: $2.9M
Placement agents: Kim, Hyun Tae
First sale: Aug 2020
Incorporated: Corporation, Delaware, 2018
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Company profile

researched Aug 2026

Inhalon Biopharma is a clinical-stage biotechnology company built around an inhaled drug platform intended for the treatment of patients with acute respiratory infections. Named indications include respiratory syncytial virus (RSV), human metapneumovirus (hMPV), influenza and SARS-CoV-2.

The company is advancing a pipeline of proprietary inhaled antibody treatments, positioned by the company as fast-acting and suitable for at-home administration. Inhalon describes the intended clinical use case as a simplified "test-to-treat" model for respiratory care.

▸Full profile — market position, technology, go-to-market

Market position

Positions itself as developing a new standard of respiratory care through inhaled antibody treatments aimed at superior effectiveness and at-home convenience relative to existing respiratory care approaches.

Differentiation is based on inhaled, fast-acting delivery of antibody treatments directly to the lungs rather than systemic administration, enabling at-home dosing and a test-to-treat treatment pathway.

Technology

The company's approach centers on an inhaled drug delivery platform for antibody therapeutics, described by the company as precedent-setting, that delivers proprietary antibodies directly to the respiratory tract to act against acute respiratory viral infections including RSV, hMPV, influenza and SARS-CoV-2.

Go-to-market

Patients suffering from acute respiratory infections, with an emphasis on at-home treatment convenience following diagnosis under a test-to-treat model.

Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.

Competitors · 4

by search overlap

Alnylam6 shared keywordsAlnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.

Avalyn Pharma Inc5 shared keywordsAvalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies. The company operates in the biotech and respiratory drug development space.

Eledon5 shared keywordsEledon Pharmaceuticals is a clinical-stage biotechnology company developing immunology-based therapies, with a focus on protecting transplanted organs from rejection and treating autoimmune and neurodegenerative diseases including ALS. The company's lead candidate is tegoprubart, an anti-CD40L antibody.

Lantern Pharma4 shared keywordsLantern Pharma is a pharmaceutical biotechnology company that applies machine learning and AI to oncology drug development, using data-driven hypothesis testing with in vitro and in vivo models. Its approach stratifies patient populations into responders and non-responders to de-risk clinical trials, develop companion diagnostics, and improve the likelihood of FDA approval at reduced cost.

Companies competing with Inhalon Biopharma for the same Google search keywords, organic and paid, via search-intersection analysis.

Legal entities · 1

corporate structure

Inhalon BiopharmaDelaware

▸Research sources · 1

primary sources listed

Inhalon Biopharmainhalon.com · web

1 public sources were cited for this profile; the first-party ones are listed here.

Frequently asked questions

What does Inhalon Biopharma do?: Clinical-stage biotech developing inhaled antibody treatments for acute respiratory infections such as RSV, hMPV and influenza.
Who founded Inhalon Biopharma?: Inhalon Biopharma was founded by Samuel Lai, Sam Lai in 2018.
Who are Inhalon Biopharma's investors?: Inhalon Biopharma's investors include Berkeley Catalyst, Flucas Ventures.
How much funding has Inhalon Biopharma raised?: Inhalon Biopharma has disclosed $2.9M raised across 1 round.
Where is Inhalon Biopharma headquartered?: Inhalon Biopharma is headquartered in Carrboro, US.